Patents Assigned to BEIGENE SWITZERLAND GMBH
  • Publication number: 20250135026
    Abstract: Antibody-drug conjugate compounds comprising a linker and methods of using such compounds are provided.
    Type: Application
    Filed: June 27, 2024
    Publication date: May 1, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Charng-Sheng Tsai, Mei-Hsuan Tsai, Xiaodong Wei, Zewei Wang, Wei Luo, Ce Wang
  • Publication number: 20250122152
    Abstract: Disclosed herein are compounds used as inhibitors of KAT6, or a pharmaceutically acceptable salt, deuterated analog, N-oxide, or tautomer thereof. Also disclosed is a pharmaceutical composition comprising a compound disclosed herein, and a method for treating or preventing a disorder or a disease responsive to the inhibition of KAT6 activity in a subject using the same. In some embodiments, the compounds are of formula (I): wherein values for the variables are disclosed herein.
    Type: Application
    Filed: September 26, 2024
    Publication date: April 17, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Qiuwen Wang, Yayi Wang, Yunhang Guo, Ling Qin, Yuxi Wang, Zhiwei Wang
  • Publication number: 20250115677
    Abstract: The present disclosure provides antibody drug conjugates comprising antibodies and antigen-binding fragments thereof that bind to human CEA and a linker-payload, a pharmaceutical composition comprising the anti-CEA antibody drug conjugate, and use of the anti-CEA antibody drug conjugate for treating a CEA-related diseases or disorders.
    Type: Application
    Filed: November 7, 2024
    Publication date: April 10, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Charng-Sheng TSAI, Mei-Hsuan TSAI, Liang QU, Xiaodong WEI, Zewei WANG, Wei LUO, Maomao HE, Zhuo LI
  • Publication number: 20250084168
    Abstract: The present invention relates generally to the field of pharmaceutical formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The formulations may further contain a histidine buffer, an inorganic salt, a sugar polyol, and a non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit low viscosity and a substantial degree of antibody stability after being subjected to thermal and other physical stress. Also provided are methods of making and methods of using such antibody formulations.
    Type: Application
    Filed: October 9, 2024
    Publication date: March 13, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Jun WU, Xiaoqing JIN, Yu JI, Sufang GU, Jian SHEN, Bo QIU
  • Publication number: 20250075002
    Abstract: The present disclosure provides for multi-specific antibodies and antigen-binding fragments thereof that bind to human MUC1 and CD16A, pharmaceutical compositions comprising said antibodies, and use of the antibodies or the compositions for treating a disease, such as cancer.
    Type: Application
    Filed: September 6, 2024
    Publication date: March 6, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Hui LI, Qiansheng REN, Liang QU, Ming JIANG, Qi LIU, Xin CHEN, Yun CHEN, Liu XUE, Wenjie WANG, Jie PAN, Zhuo LI, Xiaoyan TANG, Chichi HUANG, Ting SHAO
  • Patent number: 12234286
    Abstract: Provided are antibodies that specifically bind to TIGIT (T cell immunoreceptor with Ig and ITIM domains, WUCAM or Vstm3) and inhibit Tigit-mediated cellular signaling and activities in immune cells. The anti-TIGIT antibodies can be used to treat or diagnose cancer, infectious diseases or other pathological disorders that may be modulated by Tigit-mediated functions.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: February 25, 2025
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li
  • Patent number: 12233069
    Abstract: Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administration, quick and high-efficient release, no particular requirements on equipment, and a simple formulation preparation process, can ensure formulation stability and facilitate transportation and storage, and is suitable for large-scale production.
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: February 25, 2025
    Assignee: BeiGene Switzerland GmbH
    Inventors: Gang Qiu, Yiwei Shen, Wenyuan Fan, Shuo Xu, Huiru Lv, Jialin Bian, Zhengming Du
  • Publication number: 20250057821
    Abstract: The present disclosure provides methods of treating myeloid malignancies in a subject with a Bcl-2 inhibitor, in particularly 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide or a pharmaceutically acceptable salt thereof, in combination with azacitidine.
    Type: Application
    Filed: November 6, 2024
    Publication date: February 20, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventor: David Simpson
  • Publication number: 20250059277
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Application
    Filed: November 4, 2024
    Publication date: February 20, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Kang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
  • Publication number: 20250034257
    Abstract: The present invention relates generally to the field of pharmaceutical formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The formulations may further contain a formulation buffer, a viscosity reducer, and a non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit low viscosity and a substantial degree of antibody stability after being subjected to thermal and other physical stress. Also provided are methods of making and methods of using such antibody formulations.
    Type: Application
    Filed: October 11, 2024
    Publication date: January 30, 2025
    Applicant: BeiGene Switzerland GmbH
    Inventors: Jun Wu, Xiaoqing Jin, Yu Ji, Sufang Gu, Jian Shen, Bo Qiu
  • Publication number: 20240366769
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: November 7, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Changxin HUO, Hexiang WANG, Ruipeng QI, Zhiwei WANG, Huaqing LIU
  • Publication number: 20240368177
    Abstract: This disclosure provides 5-amino-6,8-dihydro-1H-furo[3,4-d]pyrrolo[3,2-b]pyridine-2-carboxamide derivatives, the use thereof for selectively inhibiting the activity of PRMT5 in cooperation with MTA in tumors bearing MTAPDEL mutation, and pharmaceutical compositions comprising the compounds, e.g., for treatment of various diseases including cancer.
    Type: Application
    Filed: March 27, 2024
    Publication date: November 7, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Jing LI, Sanjia Xu, Yian Guo, Zhiwei Wang
  • Publication number: 20240366770
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: June 28, 2024
    Publication date: November 7, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Changxin HUO, Hexiang WANG, Zhemin CHEN, Zhiwei WANG, Huaqing LIU
  • Publication number: 20240342292
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: May 29, 2024
    Publication date: October 17, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Bailin Lei, Huaqing Liu, Songzhe Han, Yizhou Zhao, Zhiwei Wang, Guanjun Liu, Haijun Liu
  • Publication number: 20240327417
    Abstract: Disclosed herein is a compound of Formula (I) having the following structure for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: June 4, 2024
    Publication date: October 3, 2024
    Applicant: Beigene Switzerland GMBH
    Inventors: Guoliang Zhang, Zhikun Ni, Jianzhuang Miao, Ce Wang
  • Patent number: 12103931
    Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetr a-hydropyrazolo[1,5-a]pyrimi dine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: October 1, 2024
    Assignee: BeiGene Switzerland GmbH
    Inventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi
  • Publication number: 20240317743
    Abstract: The present invention relates to a solid form, particularly a crystalline forms of Bcl-2 inhibitor 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide, pharmaceutical compositions comprising the solid form, processes for preparing the solid form, and methods of use therefore.
    Type: Application
    Filed: February 27, 2024
    Publication date: September 26, 2024
    Applicants: BeiGene, Ltd., BeiGene Switzerland GmbH
    Inventors: Desheng Yu, Gongyin Shi, Hai Xue, Yunhang Guo
  • Publication number: 20240300951
    Abstract: Disclosed herein is a compound of Formula (I) for activating T cells, promoting T cell proliferation, and/or exhibiting antitumor activity, a method of using the compounds disclosed herein for treating cancer, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: February 2, 2024
    Publication date: September 12, 2024
    Applicants: BeiGene Ltd., Beigene Switzerland GMBH
    Inventors: Guoliang Zhang, Zhikun Ni, Jianzhuang Miao, Ce Wang
  • Publication number: 20240301051
    Abstract: The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CLDN6, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 12, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Dan LI, Xiaoyan TANG, Ming LEI, Ting SHAO
  • Publication number: 20240301062
    Abstract: The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.
    Type: Application
    Filed: March 28, 2024
    Publication date: September 12, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Liu XUE, Ming LEI, Yao DING, Ruyue JI, Yun CHEN